Get the Stockscreener App
95.31
0.12%
0.11
Amedisys Inc stock is traded at $95.31, with a volume of 242.08K.
It is up +0.12% in the last 24 hours and up +3.56% over the past month.
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, and high acuity care segment. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States; the Hospice segment operates many centers designed to provide comfort and support for terminally ill patients; and the High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
See More
Previous Close:
$95.20
Open:
$95.3
24h Volume:
242.08K
Relative Volume:
0.70
Market Cap:
$3.15B
Revenue:
$2.32B
Net Income/Loss:
$82.93M
P/E Ratio:
37.82
EPS:
2.52
Net Cash Flow:
$203.54M
1W Performance:
-0.72%
1M Performance:
+3.56%
6M Performance:
-1.45%
1Y Performance:
+0.80%
1-Day Range:
$95.20
$95.53
1-Week Range:
$95.13
$96.92
52-Week Range:
$82.15
$98.95
Amedisys Inc Stock (AMED) Company Profile
Name
Amedisys Inc
Sector
Industry
Phone
(225) 292-2031
Address
3854 AMERICAN WAY, BATON ROUGE, LA
Compare AMED with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMED
Amedisys Inc
|
95.31 | 3.15B | 2.32B | 82.93M | 203.54M | 2.52 |
|
HCA
Hca Healthcare Inc
|
353.70 | 83.71B | 71.59B | 5.78B | 4.95B | 22.49 |
|
FMS
Fresenius Medical Care Ag Adr
|
28.39 | 15.02B | 20.87B | 715.14M | 1.67B | 1.2209 |
|
THC
Tenet Healthcare Corp
|
148.83 | 13.75B | 20.97B | 3.13B | 2.39B | 31.21 |
|
EHC
Encompass Health Corp
|
116.41 | 11.76B | 5.22B | 422.40M | 269.50M | 4.14 |
|
UHS
Universal Health Services Inc
|
181.78 | 11.65B | 15.42B | 1.03B | 956.84M | 15.02 |
Amedisys Inc Stock (AMED) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-07-23 | Downgrade | Truist | Buy → Hold |
| Apr-21-23 | Initiated | Cantor Fitzgerald | Neutral |
| Mar-13-23 | Initiated | Barclays | Equal Weight |
| Oct-27-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-02-22 | Downgrade | UBS | Neutral → Sell |
| Jun-29-22 | Initiated | Stifel | Hold |
| Jun-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-01-22 | Upgrade | UBS | Sell → Neutral |
| Feb-25-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-25-22 | Reiterated | Credit Suisse | Outperform |
| Feb-25-22 | Reiterated | Oppenheimer | Outperform |
| Feb-25-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-25-22 | Reiterated | Raymond James | Outperform |
| Feb-25-22 | Reiterated | Truist | Buy |
| Sep-27-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-24-21 | Initiated | UBS | Sell |
| Sep-10-21 | Initiated | Cowen | Market Perform |
| Aug-10-21 | Reiterated | The Benchmark Company | Buy |
| Aug-05-21 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-20-20 | Resumed | Barclays | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Buy |
| Jun-18-20 | Upgrade | The Benchmark Company | Hold → Buy |
| May-07-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Mar-09-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-17-20 | Initiated | Credit Suisse | Outperform |
| Nov-01-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-22-19 | Resumed | Stephens | Equal-Weight |
| Sep-17-19 | Initiated | Deutsche Bank | Buy |
| May-02-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-14-18 | Initiated | Barclays | Equal Weight |
| Nov-16-18 | Initiated | UBS | Neutral |
| Oct-30-18 | Upgrade | The Benchmark Company | Hold → Buy |
| Jul-03-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-19-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Nov-09-17 | Downgrade | The Benchmark Company | Buy → Hold |
| Nov-08-17 | Reiterated | Mizuho | Buy |
| Nov-02-17 | Upgrade | The Benchmark Company | Hold → Buy |
| Aug-21-17 | Initiated | BofA/Merrill | Neutral |
View All
Amedisys Inc Stock (AMED) Latest News
Amedisys Executive Makes Notable Stock Sale - TipRanks
US magistrate judge schedules UnitedHealth, Optum-Amedisys mediation conference - MLex
What Mediation Means For The UnitedHealth Group, Amedisys Deal - Home Health Care News
Director Kline Teresa L. was granted 1,690 shares, increasing direct ownership by 21% to 9,818 units (SEC Form 4) - Quantisnow
Director Capps Vickie L was granted 1,690 shares, increasing direct ownership by 21% to 9,818 units (SEC Form 4) - Quantisnow
Director Samuels Ivanetta Davis was granted 1,690 shares, increasing direct ownership by 29% to 7,600 units (SEC Form 4) - Quantisnow
UnitedHealth, Amedisys reach new deal to sell home health and hospice locations if merger approved - Healthcare Dive
Amedisys Deal Would Bring BrightSpring Into Range of New Markets - Hospice News
UnitedHealth, Amedisys strike deals to sell home care locations - Modern Healthcare
Press Release Distribution & PR Platform - ACCESS Newswire
Amedisys to Divest Hospice, Home Health Locations to BrightSpring, The Pennant Group - Hospice News
Amedisys (AMED) Boosts Sale Prospects with Divestiture Plan - GuruFocus
Amedisys gains after announcing new divestiture agreements in UnitedHealth deal - Seeking Alpha
Decoding Amedisys Inc (AMED): A Strategic SWOT Insight - GuruFocus
UnitedHealth: Q1 Decline Makes Undervalued Stock a Strong Buy With Dividend Upside - Investing.com
AMEDISYS INC SEC 10-Q Report - TradingView
AMED Stock Trades Flat Despite Q1 Earnings Beat, Margins Rise - TradingView
Amedisys: Q1 Earnings Snapshot - MySA
Amedisys Reports Strong Q1 2025 Financial Results - TipRanks
Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
AMEDISYS Earnings Results: $AMED Reports Quarterly Earnings - Nasdaq
Amedisys Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Amedisys (AMED) Tops Q1 Earnings Estimates - Yahoo Finance
Amedisys Inc Q1 2025 Earnings: EPS of $1.84 Beats Estimates, Rev - GuruFocus
Amedisys Reports First Quarter 2025 Financial Results - The Manila Times
Amedisys Extends Credit Facility Amid Merger Talks - TipRanks
Amedisys Q1 Profit Increases, Beats Estimates - Nasdaq
Amedisys Reports First Quarter 2025 Financial Results | AMED Sto - GuruFocus
Earnings Flash (AMED) AMEDISYS INC. Reports Q1 Adjusted EPS $1.25, vs. FactSet Est of $1.11 - marketscreener.com
Amedisys, Inc. Reports Strong Q1 2025 Financial Results with Significant Revenue and Net Income Growth - Nasdaq
US settlement talks begin in UnitedHealth-Amedisys merger case - MLex
Amedisys: 2Q Earnings Snapshot - marketscreener.com
Amedisys (AMED) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
UnitedHealth to enter mediation with DOJ over Amedisys deal - Healthcare Dive
DOJ, UnitedHealth-Amedisys lawsuit headed to mediation - Modern Healthcare
DOJ's Lawsuit Against Amedisys, UnitedHealth Group Set for Mediation - Hospice News
Shareholder Alert: Ademi LLP investigates whether Amedisys, Inc. has obtained a Fair Price in its transaction with Option Care Health - marketscreener.com
Amedisys Gets Merger Filing Claim Paused In DOJ's UHG Suit - Law360
Monthly Merger Review Snapshot - Law360
Cantor Fitzgerald maintains Amedisys stock at Neutral, $101 target By Investing.com - Investing.com Canada
Lobbying Update: $50,000 of AMEDISYS HOME HEALTH AND HOSPICE CARE lobbying was just disclosed - Nasdaq
Why Is Amedisys (AMED) Up 1.3% Since Last Earnings Report? - Yahoo Finance
Amedisys’ home health volume increases by 5% for Q4 2020 as profits soar by 63% - McKnight's Senior Living
Oppenheimer moving to Perform from Not Rated on Amedisys - TipRanks
US Bancorp DE Boosts Holdings in Amedisys, Inc. (NASDAQ:AMED) - Defense World
Raymond James maintains Amedisys stock Market Perform rating By Investing.com - Investing.com Canada
Raymond James maintains Amedisys stock Market Perform rating - Investing.com
Amedisys Inc Stock (AMED) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
1.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):